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Abstract: Human Papillomavirus (HPV) is the most common sexually transmitted virus. It is estimated that 75%
of sexually active adults transmit HPV at some instance during their life. It has long since been known that
infection with particular genotypes of this virus is a necessary factor for the development of cervical cancer.
In fact, the DNA of this virus is found in 100% of histologically-confirmed cervical cancers. Cervical cancer is
a frequent cause of female morbidity and mortality, especially in developing counties. The first part of this
study will focus on the way in which infection with specific genotypes of this virus can lead to the development
of neoplasia. This will be done in part by explanation of the life cycle of this virus as well as by clarification of
the function of the 2 oncogenes E6 and E7 that this virus possesses as part of its genome. It must be kept in
mind that not all genotypes of this virus are carcinogenic. In fact, the genotypes that are most strongly
associated with cervical cancer are HPV-16 and HPV-18, 2 genotypes that were described by the International
Association of Research on Cancer (IARC) as definite human carcinogens. These two genotypes also fall under
the heading of high-risk viruses, also because of their oncogenic potential. Given the fact that infection with
HPV is an essential step in the development of cervical cancer, prevention of infection by vaccination can
reduce the incidence of this cancer. In June 2006, the Food and Drug Administration (FDA) approved an HPV
vaccine,  Gardasil,  for  clinical  use  in  females  aged  9-26.  This  vaccine protects against 4 genotypes of HPV,
two of which are the above-mentioned HPV-16 and HPV-18. These 2 genotypes together are responsible for
over 70% of cervical cancers. It is thus, hoped that this vaccine will have major benefit on a global scale. The
2nd part of this review will focus on diverse issues related to the HPV vaccine. A brief review of the experiments
and trials that were done in the hope of developing an efficacious vaccine is given first, followed by a
discussion of the so-called Virus-Like Particles or VLPs. Finally, a review of the two HPV vaccines that were
developed, Gardasil and Cervarix, will be given. 
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INTRODUCTION other anogenital cancers are caused by infection with
A tumour results from the independent and abnormal CIN lesions contain HPV-16 DNA. On the other hand,
growth of cells (Underwood, 2004) and occurs when the HPV-18 causes 10-15% of cervical carcinomas; HPV-45
control mechanisms of proliferation of the cell are causes 7% of these lesions whilst HPV-31 causes 3% of
disturbed (Bonfiglio and Stoler, 1993). Cancer refers to cervical cancers. HPV-18 also causes 35% of cervical
any one of more than 100 diseases and is the result of a adenocarcinomas (Khan et al., 2005). 
complex mixture of environmental, nutritional and Proteins of HPV types 16 and 18 interfere with the
hereditary factors. In fact, carcinogenesis is multistep, functions of cellular regulatory pathways. This fact has
multipath and multifocal and is often driven by genetic been supported experimentally (IARC, 1995). Almost 100
instability (Lippman and Ki Hong, 2002). About 15% of case control studies have been reported that examine the
the ten million cases of cancer that develop annually relationship between HPV and cervical neoplasia and
throughout the world are attributable to infectious agents, almost all have  found  positive association. This led to
with Human Papillomaviruses (HPVs) accounting for the international agency for research on Cancer to draw
approximately 30% of these cancers (Lowy and Schiller, the following conclusion: HPV types 16 and 18 are
2006). carcinogenic to humans; HPV types 31 and 33 are
The connection between HPV  and  cervical  cancer: A than 16, 18, 31 and 33 are possibly carcinogenic to
95-100% of all cervical cancers and a high proportion of humans Table 1 (IARC, 1995). 
HPV (Fig. 1). Over 50% of cervical cancers and high grade
probably carcinogenic to humans; some HPV types other
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Fig. 1: Bar Graph showing the fact that HPV is involved EXPERIMENTAL EVIDENCE
in a number of different cancers, but it is most
strongly associated with cervical cancer. Source:
h t t p : / / e n . w i k i p e d i a . o r g / w i k i / I m a g e :
Cases_of_HPV_cancers_graph. png
Table 1: Gynaecologic lesions associated with human papillomavirus
Type Lesion
6a-f Condylomata acuminata; CIN I, II and III;
VIN I, II and III
11a, b Condylomata acuminata; CIN I, II and III
16 Condylomata acuminate; CIN I, II and III;
VIN I, II and III; Bowenoid papulosus; 
Carcinoma of the cervix
18 Carcinoma of the cervix
30 CIN
31 CIN; Carcinoma of the cervix
33 Bowenoid papulosus
CIN; Carcinoma of the cervix
34 Bowenoid papulosus
35, 39 CIN; Carcinoma of the cervix
40, 42, 43, 44 CIN
45, 51 CIN; Carcinoma of the cervix
52 Carcinoma of the cervix
56 CIN
58 Carcinoma of the cervix
CIN: Cervical Intraepithelial Neoplasia; VIN: Vulvar Intraepithelial
Neoplasia; Source: DiSaia and Creasman (2002)
The benefit of a vaccine: The purpose of active
immunization is to induce an immune response by giving
antigen in such a way that pathogenic effects are avoided
but effective immunity is generated. The 1st exposure to
antigen, as in vaccination, induces a primary response
that generates a primed population of memory cells.
Subsequent exposure to antigen leads to a faster and
stronger secondary immune response (Onon, 2003). A
vaccine is considered to be efficacious if it reduces the
incidence of vaccine type-specific persistent infections
and of associated cervical intraepithelial neoplasia. 
Since cervical tumours are viral in origin, generation
of antiviral immunity by vaccination could have major
benefits on a global scale. Vaccine development has
involved attention on the design of vaccine components
(e.g., antigen expression, choice of adjuvants, formulation
and  patent  rights)  and the development of serologic
tests to  measure  immunity and tests to detect the
specific type of HPV infection. HPV vaccine development
has been considerably advanced due in part to the
production of Virus-Like Particles (VLPs) (Lowy and
Schiller, 2006), which mimic the structure of the HPV virion
but do not contain genetic material. They can be
manufactured by exogenous expression of L1 in a variety
of cell types, including bacterial, yeast, insect and
mammalian cells. VLPs are noninfectious and
nononcogenic, making them ideal candidates for use in
HPV vaccine production. 
Experiments supporting, the carcinogenicity of
specific HPV types have been performed and the
following conclusions were drawn: 
C Overexpression of HPV genes in high-risk HPV
infected cells leads to chromosomal instability
C Immortalisation of human cells, that is, their
continuous in vitro growth, is restricted to high-risk
viruses. Moreover, chromosomal abnormalities and
alterations in ploidy are regularly detected in HPV-
immortalised cell lines
C Immortalized cells can subsequently convert to
malignant growth. This involves the modification of
genes engaged in the control of HPV transcription
and which are activated by a paracrine regulatory
pathway
C HPV 16 and 18 influence transcription from certain
promoters
C The E2, E5, E6 and E7 open-reading frames of several
HPV genotypes contribute to the immortalization/
transformation  function  of  the  viruses.
Transformation is defined as the ability to induce
tumours in  immunocompromised  hosts (IARC, 1995)
THE HPV LIFE CYCLE
HPV infection occurs when the virus enters the
epithelium  (through  a  cut  or  minor injury in the skin)
and reaches the basal cells, especially those at the
transformation zone. The virus loses its capsid, its DNA
enters the basal cell and reaches the nucleus, where it is
integrated in the host cell DNA. Therefore, all cells
derived from this basal cell will be infected with the virus
because they will all contain the viral genome. These
infected cells reach the upper part of the epithelium where
they start produce the viral proteins and mature viral
particles (Palefsky, 2002). 
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Koilocytosis occurs: Koilocytes are large, rounded HPV-positive and HPV-negative women. Regions that
vacuolated cells (Craig  and Lowe, 2003) with an enlarged undergo loss of heterozygosity in cervical cancer include
and irregular nucleus surrounded by a clear space 1p, 1q, 2q, 3q, 4q, 5p, 5q, 6p, 6q, 10q, 11p, 11q, 17p, 17q,
(Palefsky, 2002). The koilocyte is the histological hallmark 18p (IARC, 1995). 
of infection with HPV (Craig  and Lowe, 2003). During this
stage, mild dysplasia-there is rapid viral replication, Interaction of HPV with environmental agents: HPV and
making this stage the most contagious one. Moderate and Herpes Simplex Virus (HSV) may act as syncarcinogens,
severe dysplasias, on the other hand, are characterized by but this has not been proven. HPV expression in vitro is
small immature cells because even the top layers of the also influenced by Human Herpesvirus 6 (HHV-6); in fact,
epithelium, which normally do not replicate, start HHV-6 increases E6 and E7 mRNAs in infected carcinoma
multiplying. Severe dysplasia is potentially pre-cancerous cell lines.
(Palefsky, 2002). Hormones and antioestrogens alter the expression of
HPV-INDUCED CERVICAL CARCINOGENESIS with the transcription of the E6 and E7 genes in HPV-18-
HPV-targeted cellular proteins-p53 and pRB: Alteration markedly increased in human ectocervical cells exposed to
in the p53 protein, the product of the tumour suppressor glucocorticoid or progesterone. 
gene p53, is a common event that occurs during the The chemotherapeutic agent, tamoxifen, stimulates
development of most carcinomas. One of the HPV- the proliferation of an HPV-16-positive cervical carcinoma
encoded proteins, E6, can interact with and functionally cell line if present at low concentrations. Mutagens and
inactivate the p53 protein. This suggests that somatic immunosuppressants also cooperate with HPV in various
alteration within the p53 gene itself may not be a ways. UV and X-ray radiation, by inducing mutations,
necessary step during the development of HPV- may increase the expression of viral oncoproteins though
associated cancers. In fact, it has been observed that p53 direct interference with factors that down-regulate viral
mutations are extremely rare in HPV-positive cancers. On transcription or replication (IARC, 1995). 
the other hand, the HPV-encoded oncoprotein E7 has
been shown to interact with and inactivate the function of Recent studies and clinical trials 
pRB (retinoblastoma protein), a tumour suppressor Portland study: This examined data from 20, 514 women,
protein. An inverse correlation between HPV positivity who received routine cytological screening in a prepaid
and pRB mutations has also been noted. A high health plan. It was found that women who tested positive
expression level of these viral oncoproteins is needed for for HPV 16 or 18 were diagnosed with CIN III or cervical
the malignant phenotype (IARC, 1995). cancer more often than women who tested positive for
Viral DNA integration: Viral DNA can be maintained negative for HPV. Khan et al. (2005) concluded that HPV
episomally in the nucleus of the infected cell/s. The 16 and 18 are potent carcinogens and should be more
detection of this genetic integration in cervical neoplasia effectively targeted in clinical practice.
is frequently associated with malignant progression. This
is because integration is postulated to: The ALTS clinical trial: Castle et al. ( 2005) found that in
C Deregulate E6 and E7 expression through loss of viral cervical cytology, having a baseline, prevalent HPV
transcription regulators such as E2 and/or escape infection was associated with a very high absolute risk of
from cellular control through transcriptional initiation developing Cervical Intraepithelial Neoplasia (CIN) 3 or
of these regions from flanking cellular promoters cervical cancer over a 2 year period. This corresponds to
C Increase the stability of the E6/E7 in mRNA, giving a 5 fold greater risk than  the  collective  risk  attributable
cells with integrated viral sequences a selective to  other  prevalent  oncogenic HPV type infections.
growth advantage Castle et al. (2005), also demonstrated the potential utility
C Transcriptionally activate cellular proto-oncogenes of adjunctive testing of HPV 16 and possibly HPV 18 in a
by viral promoters (IARC, 1995) screening population.
Chromosomal alterations: Although, these non-random THE HPV VACCINE
alterations are present in cytogenetic analyses of cervical
carcinomas and although, it is known that they play a role Studies  and  trials:  Liu  et  al.  (2002)  developed
in  tumour  development,  they  have been   found  in both recombinant Adeno-Associated Virus (rAAV) encoding
the HPV genome. Dexamethasone interferes differentially
positive carcinoma cell lines. HPV-16 expression is
another oncogenic HPV type or women who tested
young women with either equivocal or mildly abnormal
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HPV-16 E7 Cytotoxic T-Lymphocyte (CTL) peptide DNA
fused with heat shock protein (hsp) DNA as a tumor
vaccine. This uses hsp as a carrier protein and delivery by
rAAV vector.
Emeny et al. (2002 ), demonstrated that a recombinant
HPV-11 L1 VLP vaccine could elicit HPV-specific antibody
and proliferative T-cell responses in 18-25 year old women
not exposed to HPV-11.
Peng et al. (2004), investigated the feasibility of the
HPV-16 oncoprotein E6 as a target for vaccine
development and demonstrated that the linkage of
Calreticulin (CRT) to E6 elicits an E6-specific CD8  T-cell+
immune response in C57BL/6 mice. Furthermore,
vaccination with DNA encoding CRT linked to wild-type
E6 can protect mice against challenge with an E6-
expressing tumor cell line. This suggests that the amino
acid 50-57 sequence of E6 is important for antitumor
effects.
According to Baud et al. (2004), the development of
a Salmonella-based vaccine against HPV infection and
associated lesions had the theoretical advantage of
inducing long-lasting systemic and mucosal immunity
with a single oral vaccination. However, this vaccine was
not tested in women due to several drawbacks.
Virus-Like Particles (VLRs): Empty viral capsids,
termed Virus-Like Particles (Fig. 2) (VLPs) are synthesized
using microbial or cellular expression systems and
represent the leading candidate vaccine for the treatment
or prevention of cervical cancer in humans. VLPs are
purified, concentrated, distributed into aliquots and
combined with an adjuvant. Vaccination with L1 VLPs
derived from species-specific papillomaviruses neutralizes
virus and, in animal models, protects against the
development of lesions.
HPV VLPs and chimeric VLPs are immunogens that
are able to elicit potent anti-viral/tumor B and T-cell
responses. VLPs were found to bind very well to human
and mouse immune cells that expressed markers of
Antigen-Presenting Cells (APCs) such as MHC class II,
CD80 and CD86, including dendritic cells, macrophages
and B cells. Dendritic cells, as the most potent inducers of
immune responses, play a central role in VLP-induced
immunity. It was clearly demonstrated that immature
human dendritic cells were fully activated by chimeric
HPV16 VLPs and were subsequently capable of inducing
endogenously processed, epitope-specific human T-cell
responses in vitro (Mandic and Vujkov, 2004). 
Gardasil and cervarix: Gardasil, produced by Merck, is a
quadrivalent vaccine that offers protection against HPV
types  6  and  11,  which are responsible for 90% of genital
Fig. 2: Human Papillomavirus (HPV) L1 Virus-Like
Particle (VLP). Source: http://www.urmc.
rochester.edu/ GEBS/faculty/Images/vlps. jpg
warts and HPV types 16 and 18, which are associated with
70% of cervical cancers. According to a phase III study,
the vaccine is 100% effective in preventing HPV 16 and 18
related cervical precancerous and cancerous changes.
(Mayor,  2005). This is the first vaccine to protect against
cancer  and  against a sexually transmitted disease
(Tanne, 2006). The vaccine is formulated with a classic
alum adjuvant. 
Gardasil was approved by the food and drug
administration on the 8th of June 2006 and by the
European medicines agency in late September 2006 for use
in girls and women aged 9-26 years (Tanne, 2006). It has
also been approved by regulatory agencies in Australia,
Brazil, Canada, Mexico and New Zealand. 
Optimal protection against infection with HPV
requires a course of three doses of Gardasil, with 2
months between the 1st and 2nd doses and 4 months
between the 2nd and 3rd doses. The cost is approximately
$120 and €120/dose in the United States and Europe,
respectively.
Cervarix, developed by GlaxoSmithKline, is a bivalent
vaccine that protects against HPV types 16 and 18. The
vaccine is formulated with a new ASO4 adjuvant that
contains monophosphoryl lipid A, a derivative of bacterial
cell walls. ASO4 is also incorporated in Fendrix (hepatitis
B vaccine) and a candidate vaccine against herpes simplex
virus, neither of which are approved for use in Canada
(Dawar et al., 2007).
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Efficacy: Prophylactic HPV vaccination is mostly individuals already infected with either HPV16 or HPV18
efficacious in women  aged  15-25  years, who receive all from developing cervical cancer,  which  can occur up to
3 vaccine doses and who have no prior abnormal results 10 years after infection. It will also not prevent individuals
from Pap screening (Rambout et al., 2007). For this reason, infected with other oncogenic strains of HPV from
Gardasil should be offered to females before they are at developing cancer (Honey, 2006). For this reason, all
risk of HPV infection (Dawar et al., 2007) vaccinated females should continue to participate in Pap
Efficacy against persistent infection is 94 and 80% for smear screening programs because they remain at risk of
Gardasil and Cervarix, respectively. Vaccine efficacy for adverse gynecological outcomes from other high risk HPV
precancerous lesions caused by HPV types 16 and 18 is genotypes (Dawar et al., 2007). 
98% for Gardasil and 90% for Cervarix. In addition,
Gardasil offers 100% protection against vulvar Vaccine acceptance: Underestimates of both the level of
intraepithelial neoplasia (grade 2-3) and vaginal risk  and  the  severity  of  HPV-associated  disease  may
intraepithelial neoplasia (grade 2-3) caused by HPV types be barriers to vaccine acceptance. Hence, vaccine
16 and 18. Gardasil is also 96% efficacious in preventing acceptance can be maximized by effectively
genital warts. Moreover, in the Cervarix trials, modest communicating the risks associated with HPV infection
cross protection was documented against infection by and the benefits of vaccination. Educational initiatives
HPV type 45 (vaccine efficacy 60%) and to a lesser extent, targeted towards parents and the public in general are
against HPV types 31 and 52 (vaccine efficacy 36 and invaluable in fostering positive attitudes towards
32%, respectively). vaccination. 
Both Gardasil and Cervarix are highly immunogenic. More than 70% of the parents of girls between the
In fact, the vaccine-induced antibody titres are much ages of 8 and 18 years, who were surveyed in a national
higher than those induced by natural HPV infections. study showed an intention of having their daughters
Gardasil-induced antibody titres peak 7 months following receive the HPV vaccine in school based, publicly funded
the start of the vaccine series. The titres then decline and vaccination programs for girls 11 and 12 years of age. Just
reach a plateau 18-24 months later. This plateau is over 20% of the parents of girls expressed concerns about
maintained for at least 5 years, with 5 year levels that are the influence of the HPV vaccine on sexual behaviour
similar to the titres naturally induced by HPV types 6 and (Ogilvie et al., 2007).
18 and that are higher than the titres naturally induced by
HPV types 11 and 16. Cervarix-induced antibody titres CONCLUSION
follow the same profile as Gardasil, but the 18 month
plateau  level  is  many-fold higher than the levels induced A recent advance in the history of medicine was the
by natural infection and after 51-53 months, 100% of development of 2 HPV vaccines that prevent a person
women remain seropositive for both HPV types 16 and 18. from becoming infected with HPV. Since prolonged and
Titres for both vaccines are 1.7-2.4 times higher in persistent infections with the oncogenic genotypes of
young adolescents than in women aged 16-26 years. In HPV are the main reason behind the development of
fact, 2 doses of Gardasil (0 and 2 months) in adolescents cervical cancer, preventing infection with these subtypes
aged 10-15 years produced antibody titres that were is the most effective way to eradicate cervical cancer. 
equivalent  to  those  produced  by   3   doses   (0,  2 and Educational initiatives targeted mainly towards
6 months) in women aged 16-26 years for 3 of the 4 parents to have their children immunized against HPV at
vaccine genotypes (Dawar et al., 2007). an early age are of immense importance. The vaccine will
Some scientists consider the prevention of HPV be of no use if the person receiving, it has already been
infection in men (by vaccinating them), not only to reduce infected with the HPV subtypes that the vaccine is
rates of anal cancer and genital warts in men, but also to expected to protect the person from. It is thus, of crucial
reduce cervical cancer in women. Studies are being importance that the vaccine is given before a person is
conducted as regards this issue (Geipert,  2005). exposed to HPV. The vaccine is also more efficacious at
Drawbacks: The vaccine might be too expensive for antibody titres and therefore, a stronger immune response
developing countries, which have much higher death in young females than in adult ones. 
rates from cervical cancer than do developed countries, The 2 HPV vaccines that have been manufactured,
largely because they lack organized screening programs. Gardasil and Cervarix, protect against HPV-16 and HPV-18,
Also, although, Gardasil protects against infection with which are responsible for the majority of cervical cancers.
HPV6, HPV11, HPV16 and HPV18, it will not prevent Yet,  some  30%  of  cervical  cancers  are  caused by other
a young age; in fact, a given dose induces higher
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HPV types that these vaccines do not protect against. For Geipert, N., 2005. Vaccinating Men for HPV: New Strategy
this reason, cytology screening must still be done on
women who have been vaccinated against HPV-16 and
HPV-18, because they may still develop cervical cancer.
The  incidence of cervical cancer will be reduced further
if not only women but also men are immunized against
HPV. Once again, developing countries pose a problem
because people living here may not afford to take the
vaccine. 
The introduction of the HPV vaccine will hopefully
once more lead to a substantial decrease in cervical cancer
incidence, following the decrease that was observed on
the introduction of the Papanicolaou smear. A greater
initiative should be undertaken, however, as regards
developing countries, which will probably be the last ones
to afford to take the vaccine; countries, which also lack
organized screening programmes, lack education about
the disease and lack appropriate treatment once the
disease manifests itself. 
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